Trial Closed

Summary

This partially randomized phase III trial studies the side effects of different combinations of risk-adapted chemotherapy regimens and how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia or B-lineage lymphoblastic lymphoma that is found only in the tissue or organ where it began (localized). Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy), giving the drugs in different doses, and giving the drugs in different combinations may kill more cancer cells.

Description

 

After completion of study treatment, patients are followed up periodically for 10 years from study entry.

Principal Investigator

Mohamad Badawi

Study Coordinator

Lisa Luikart

Research Contact

Lisa Luikart - lisa.luikart@vandaliahealth.org

Sex

All

Age

1-30

NCT Number

NCT01190930

IRB Number

10-09-2262

Phase(s)

3

Link

None